Sudeep Pharma Ltd. is a leading Indian manufacturer of high-quality excipients, mineral-based ingredients, and specialty chemicals used across the pharmaceutical, food, nutraceutical, and personal-care industries. With decades of expertise, the company has built a strong reputation for reliability, innovation, and global-quality standards.
What the Company Does
Sudeep Pharma specializes in producing calcium and mineral-based excipients, which are essential raw materials for tablets, capsules, syrups, nutrition products, and cosmetic formulations. Its core product categories include:
- Calcium Carbonate (Precipitated & Coated)
- Calcium Citrate & Calcium Phosphate
- DC (Directly Compressible) Grade Excipients
- Mineral Supplements & Fortification Ingredients
- Customized pharma-grade chemical solutions
These products support pharmaceutical companies in improving drug stability, absorption, and overall formulation quality.
Industry Reach
The company caters to a wide range of sectors, such as:
- Pharmaceuticals
- Food & Beverage
- Nutraceuticals & Dietary Supplements
- Veterinary Products
- Cosmetics & Personal Care
Sudeep Pharma supplies to domestic clients as well as international markets, and it adheres to stringent global standards such as GMP, ISO, and DMF compliance.
Technology & Quality Strength
Sudeep Pharma is known for:
- Advanced R&D and formulation support
- State-of-the-art, automated manufacturing units
- Strict quality testing at every stage
- Consistent product performance for high-volume production
- Ability to develop customized excipient solutions
Its focus on innovation helps companies create safer, more effective, and stable formulations.
Key Strengths
- Strong legacy in mineral-based excipients
- Wide product portfolio serving multi-industry needs
- Long-term relationships with leading pharma brands
- Robust quality systems and certifications
- Global supply capabilities
Future Outlook
With rising demand for pharmaceuticals, health supplements, and fortified foods, Sudeep Pharma is positioned for sustainable growth. The company continues to enhance its production capacity, expand into high-value excipients, and strengthen its global reach—solidifying its role as a trusted partner in the healthcare and wellness supply chain.
Sudeep Pharma Ltd. IPO Timetable
| Particular | Date |
| IPO Open Date | 21 Nov 2025 |
| IPO Close Date | 25 Nov 2025 |
| Allotment Date | 26 Nov 2025 |
| IPO Listing Date | 28 Nov 2025 |
Sudeep Pharma Ltd. IPO Details
| Issue Type | Book building IPO |
| Face Value | Rs. 1 Per Equity Share |
| IPO Price | Rs. 563 to 593 Per Equity Share |
| Market Lot | 25 Share |
| ISIN Code | |
| Listing At | NSE, BSE |
| Issue Size | Rs. 895 Crore. |
Sudeep Pharma Ltd. IPO Lot Size
| Application | Lots | Shares | Amount |
| Minimum | 1 | 25 | Rs. 14825 |
| Maximum | 13 | 325 | Rs. 192725 |
| Small HNI (Minimum) | 14 | 350 | Rs. 207550 |
| Big HNI (Minimum) | 68 | 1700 | Rs. 1008100 |
Sudeep Pharma Ltd. IPO Allotment Status
Click Here To Check IPO Allotment Status Sudeep Pharma Ltd. IPO
Click Here To Get ASBA Forms Sudeep Pharma Ltd. IPO
Company Financials :
| Particular | 31 March 2025 | 31 March 2024 | 31 March 2023 |
| Total Assets | 717.17 | 513.87 | 420.11 |
| Total Revenue | 511.33 | 465.38 | 438.26 |
| Profit After Tax | 138.69 | 133.15 | 62.32 |
Company Promoters:
Sujit Jaysukh Bhayani, Avani Sujit Bhayani, Shanil Sujit Bhayani, Sujeet Jaysukh Bhayani HUF, Riva Resources Private Limited, and Bhayani Family Trust are the promoters of the company.
Objects of this Issue:
- Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I
- General Corporate Purposes.
Registrar & Company Details
| Company Contact Information | IPO Registrar |
| Sudeep Pharma Ltd. 129/1/A, GIDC Estate, Nandesari, Vadodara, Gujarat, 391340 Phone: +91 265 284 0656 Email: cs.sudeep@sudeepgroup.com Website: https://www.sudeeppharma.com/ | MUFG Intime India Pvt.Ltd. Phone: +91-22-4918 6270 Email: sudeeppharma.ipo@in.mpms.mufg.com Website: https://linkintime.co.in/Initial_Offer/public-issues.html |
Risk Discloer :-Investing in Initial Public Offerings (IPOs) involves significant market risks. The information provided in this blog post is for educational and informational purposes only and should not be treated as investment advice or a recommendation to subscribe to any IPO. Investors must carefully read the Red Herring Prospectus (RHP), company financials, and all risk factors before investing.
IPO allotment is not guaranteed, and the listing price may differ from expectations due to market demand, business fundamentals, and overall market conditions. Newly listed companies may experience high volatility in the initial days of trading. Past performance of other IPOs does not indicate or assure future results.
Investors should evaluate their risk appetite, financial objectives, and seek independent professional advice before making any investment decisions.
